Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Selcia Doubles Its Radiolabeling Labs

by Michael McCoy
December 19, 2011 | A version of this story appeared in Volume 89, Issue 51

[+]Enlarge
Credit: Selcia
Selcia has doubled its capacity to conduct carbon 14 radiolabeling projects at its facility in Ongar, Essex, England. The company says it has been preparing radiolabeled active pharmaceutical ingredients for customers with compounds in Phase I clinical trials following certification by British authorities in September 2010.
Credit: Selcia

Selcia has doubled its capacity to conduct carbon-14 radiolabeling projects in Ongar, Essex, England. The company says it has been preparing radiolabeled active pharmaceutical ingredients for customers with compounds in Phase I clinical trials since September 2010, after certification by British authorities. Drug companies create radiolabeled versions of developmental compounds for metabolism, mass-balance, and microtracer studies, Selcia notes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.